We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Assays Aid Analysis of Biomarkers

By HospiMedica staff writers
Posted on 31 Mar 2006
Two new assays have been launched that are commercially available for quantitative biomarker analysis. More...


The Epityper assay and the Qge iplex multiplex assay were developed by Sequenom (San Diego, CA, USA) for use with the company's Massarray system. The assays are directed towards the methylation-marker analysis market and the gene-
expression analysis market, respectively.

The Epityper assay is a novel enabling tool for DNA methylation-marker research. DNA methylation markers are a relatively new class of biomarkers that are useful because of there correlation to gene activity. High levels of cytosine methylation in genomic regions called CpG islands are often associated with decreased or completely inhibited gene expression. Researchers believe that DNA methylation patterns play an important role in early cancer detection and prognosis. The assay is important in other fields by providing quantitative results in the form of methylation ratios in targeted genomic regions.

The second assay, the Qge iplex multiplex assay, is a research tool that enables quantitative gene-expression analysis. While other technologies generally provide for an analysis of only one to four genes per reaction, Sequenom's multiplex assay provides simultaneous quantitative results for 20 or more genes per reaction. This results in reduced reagent costs and more data per time interval. Quantitative gene-expression analysis provides information that helps researchers assess disease prognosis and evaluate patient response to treatment.

The Epityper assay and the Qge iplex multiplex assay are to be presented at the annual meeting of the American Association of Cancer Research in Washington (DC, USA) in April 2006.



Related Links:
Sequenom

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hypodermic Syringe
SurTract™ Safety Syringe
Syringe Pump
SP50 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.